SCOT Trial Confirms 3-Month Adjuvant Chemotherapy Noninferior to 6-Month Standard for Colorectal Cancer
Key Insights
The phase III SCOT trial demonstrated noninferiority of 3-month versus 6-month adjuvant oxaliplatin plus fluoropyrimidine chemotherapy for overall survival in colorectal cancer (search) patients.
Among 6,088 patients, 5-year overall survival was identical at 82.4% for both treatment durations, with noninferiority confirmed for CAPOX (search) but not FOLFOX (search) regimens.
The shorter treatment duration significantly reduced toxicities including sensory neuropathy, diarrhea, and neutropenia while maintaining equivalent survival outcomes.
Final results from the UK-based SCOT trial have established that 3 months of adjuvant oxaliplatin plus fluoropyrimidine chemotherapy is noninferior to the standard 6-month regimen for overall survival in patients with colorectal cancer (search). The findings, published in the Journal of Clinical Oncology, provide definitive evidence supporting shorter treatment duration with reduced toxicity and equivalent survival outcomes.
Trial Design and Patient Population
The international randomized phase III SCOT trial enrolled 6,088 patients between March 2008 and November 2013, randomly assigning them to receive either 3 months (n=3,044) or 6 months (n=3,044) of adjuvant chemotherapy. Among participants, 4,109 patients (67.5%) received capecitabine and oxaliplatin (CAPOX (search)), while 1,979 patients (32.5%) received fluorouracil, leucovorin, and oxaliplatin (FOLFOX (search)).
Eligible patients were 18 years or older with high-risk stage II or stage III adenocarcinoma (search) of the colon or rectum who had undergone curative resection. All participants had WHO performance status of 0 or 1, adequate organ function, and at least 5 years of life expectancy.
Overall Survival Outcomes
The primary analysis revealed identical 5-year overall survival rates of 82.4% (95% CI = 80.9%-83.8%) in both the 3-month and 6-month treatment groups (hazard ratio = 0.96, 95% CI = 0.86-1.07, noninferiority P = .0033). A total of 1,255 overall survival events occurred during the extended follow-up period.
However, important differences emerged when analyzing results by chemotherapy regimen. Among patients receiving CAPOX (search), 5-year overall survival was 82.5% (95% CI = 80.8%-84.2%) in the 3-month group versus 81.4% (95% CI = 79.7%-83.2%) in the 6-month group (HR = 0.90, 95% CI = 0.79-1.03, noninferiority P = .00052).
For patients receiving FOLFOX (search), 5-year overall survival was 82.0% (95% CI = 79.6%-84.6%) in the 3-month group compared to 84.4% (95% CI = 82.0%-86.8%) in the 6-month group (HR = 1.10, 95% CI = 0.90-1.34, noninferiority P = .38354). Noninferiority was not established for the FOLFOX regimen.
Subgroup Analysis by Disease Stage and Risk
Among patients with stage III colon cancer (search), overall survival was 81.0% in both treatment groups. In low-risk cases, 5-year overall survival was 91.0% with 3 months of treatment versus 89.1% with 6 months (HR = 0.87, 95% CI = 0.70-1.07). For high-risk cases, survival rates were 69.5% and 71.7%, respectively (HR = 1.02, 95% CI = 0.88-1.17).
Noninferiority of 3-month treatment was confirmed for low-risk stage III patients (P = .0071) but not for high-risk patients (P = .072).
Rectal Cancer Outcomes
Among 1,101 patients with rectal cancer (search), 5-year overall survival was 88.6% in the 3-month group versus 87.3% in the 6-month group (HR = 0.74, 95% CI = 0.55-1.00). For those receiving CAPOX (search), survival rates were 89.8% versus 88.1% (HR = 0.67, 95% CI = 0.47-0.97), while FOLFOX (search) patients had survival rates of 86.4% and 85.6% (HR = 0.91, 95% CI = 0.55-1.53).
Safety and Toxicity Profile
The safety analysis, evaluating 434 patients in each treatment group, demonstrated significantly higher toxicity rates with 6-month treatment. The longer duration group experienced significantly more grade 3-5 adverse events including diarrhea (P = .033), neutropenia (P = .031), pain (P = .014), hand-foot syndrome (P = .031), and sensory neuropathy (P < .0001).
The most common grade 3-5 adverse events across both groups were sensory neuropathy, diarrhea, neutropenia, fatigue, pain, nausea, and hand-foot syndrome.
Clinical Implications
"These final SCOT results provide further evidence that 3 months of adjuvant chemotherapy can be recommended for most localized colon or rectal cancers, with no statistically significant OS advantage of 6 months of treatment in any cohort," stated lead author Timothy Iveson, MD, FRCP, from the University of Southampton.
The investigators emphasized that when deciding treatment duration for high-risk stage III disease, clinicians should consider that there is no significant overall survival advantage for 6 months of therapy while highlighting the additional toxicities, particularly cumulative neuropathy, and increased hospital visits associated with longer treatment.
The study authors concluded that "SCOT has shown noninferiority for overall survival with 3 months of adjuvant chemotherapy treatment, which should be recommended for most patients." The findings support a paradigm shift toward shorter adjuvant treatment duration, reducing treatment burden while maintaining equivalent survival outcomes for the majority of colorectal cancer (search) patients.